Influenza Vaccine Candidates 2024
Influenza Vaccine Candidates 2024
A report indicates over 110 influenza vaccine candidates are under development in 2024.
A mosaic influenza nanoparticle vaccine (FluMos-v1) is unique in that it is designed to co-display four recently circulating haemagglutinin (HA) strains. A phase 1 clinical study demonstrates that FluMos-v1 nanoparticles are predominantly quadrivalent. Imaging by TIRFM allowed direct visualization of the co-localization of HA trimers from multiple strains, and imaging of more than 10 thousand nanoparticles revealed individual nanoparticles with four, three, two, and one color.
CSL sa-mRNA bicistronic influenza vaccine candidates produced a potent, cross-reactive immune response against pandemic and seasonal influenza strains A(H5N1) and A(H1N1). In addition, the mRNA platform recently reported results from a significant Phase III vaccine study, meeting its primary and secondary endpoints of infection prevention and severe disease with a favorable safety and tolerability profile.
Cidara Therapeutics's CD388 is a highly potent long-acting antiviral immunotherapy in phase 1 study, designed to deliver universal seasonal and pandemic influenza prevention.
CureVac's second-generation mRNA influenza vaccine candidate, CVSQIV, was developed with GSK. An extended preliminary phase 1 data from Joint COVID-19 and Flu mRNA Vaccine Development Programs was launched on May 8, 2023. The Phase 1 study's best-performing candidate providing broad antigen coverage against WHO-recommended flu strains selected for Phase 2, following positive data from Phase 1 interim analysis. Dosing of the first Phase 2 participant is anticipated in Q4 2023.
The Emergex universal influenza vaccine candidate is designed to induce CD8+ T cells specific to highly conserved parts of the influenza virus from both the positive and negative sense reading frames.
Flu-v Influenza Vaccine is a synthetic universal flu vaccine candidate that offers protection across a broad influenza spectrum forcing 1+NP forcing vaccine candidate consisting of MVA, a replication-deficient pox viral vector safely tested in thousands of patients, generates strong immune reaction against Matrix 1 Nucleoprotein influenza antigens.
NasoVAX is a recombinant intranasal vaccine developed for both seasonal and pandemic use.
NanoFlu is a quadrivalent recombinant hemagglutinin (H.A.) protein nanoparticle influenza vaccine produced by Novavax in its SF9 insect cell baculovirus system. NanoFlu uses H.A. amino acid protein sequences similar to the recommended wild-type circulating virus H.A. sequences. In addition, NanoFlu contains Novavax's patented saponin-based Matrix-M™ adjuvant. CD388 (drug-Fc conjugate) is a highly potent, long-acting antiviral immunotherapy designed to deliver universal prevention and treatment of seasonal and pandemic influenza. Cidara Therapeutics intends to initiate a Phase 1 study in healthy volunteers in 2022.
The U.S. NIH's BPL-1357 is a whole-virus vaccine candidate comprising four non-infectious, chemically inactivated, low-pathogenicity avian flu viruses conducting a phase 1 study.
Novavax investigational influenza (qNIV) vaccine is our quadrivalent nanoparticle vaccine candidate, targeting seasonal flu. qNIV is designed using our recombinant technology, with four forms of wild-type hemagglutinin (H.A.) protein from the influenza virus as antigens. Antigens are organized into distinct nanoparticle complexes recognized by the immune system, working in concert with our Matrix-M™ adjuvant.
Osivax' OVX836 targets the nucleoprotein (N.P.), a highly conserved internal antigen. Unlike surface antigens, the N.P. is much less likely to mutate, alleviating the need for annual vaccination updates. The latest results from the Phase 2a dose-optimization study (OVX836-003) found that OVX836 maintained an excellent safety profile at all doses and provided protective efficacy in reducing PCR-confirmed influenza-like illnesses by 78%. Topline results from both studies are anticipated in the first half of 2023.
Sinovac Biotech Ltd.'s two-dose inactivated quadrivalent influenza vaccine is conducting a phase 3 study with children in Chile.
Revelation Biosciences Inc. intranasal REVTx-99a is for the preventive treatment of H3N2 influenza (influenza A and B) infection in healthy humans, parainfluenza, rhinovirus, respiratory syncytial virus, and SARS-CoV-2 including its variants.
Redeeflu (M2SR) is a nasal vaccine candidate utilizing a proprietary M2 deleted, single replication influenza virus.
Vaxess Technologies, Inc. MIMIX-Flu Vaccine Patch is conducting Phase I Clinical Trial, a first-in-man trial of VX-103. On June 5, 2023, the Company stated the MIMIX-Flu vaccine patch elicited robust, durable, and broadly protective immune responses. And titers did not differ significantly for the two dose levels, indicating a fractional dose can be delivered without substantially impacting immunogenicity.
PDS Biotechnology Corporation's investigational universal influenza vaccine PDS0202 demonstrated active neutralization across multiple influenza viruses.
The universal influenza vaccine candidate FluMos-v2 (VRC- FLUMOS0116-00-VP, start date: 2023-08-09) was designed by researchers at NIAID's Vaccine Research Center (VRC) and is conducting a phase 1 clinical trial. FluMos-v2 is intended to induce antibodies against various influenza virus strains by displaying part of the influenza virus hemagglutinin (H.A.) protein in repeating patterns on self-assembling nanoparticle scaffolds (SAPNs). Exposure to these harmless fragments of virus proteins prepares the immune system to recognize and fight the virus. When tested in animals, the experimental vaccine resulted in robust antibody responses. It is an adaptation of an earlier U.S. NIH universal flu vaccine candidate, FluMos-v1, which began first-in-human testing in 2021 and is still undergoing clinical trials.
